Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha

Cancer Res. 2009 Aug 15;69(16):6445-53. doi: 10.1158/0008-5472.CAN-09-1001. Epub 2009 Aug 4.

Abstract

We previously showed that nicotine stimulates non-small cell lung carcinoma (NSCLC) cell proliferation through nicotinic acetylcholine receptor (nAChR)-mediated signals. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) has also been shown to induce NSCLC cell growth. Here, we explore the potential link between nicotine and PPARbeta/delta and report that nicotine increases the expression of PPARbeta/delta protein; this effect was blocked by an alpha7 nAChR antagonist (alpha-bungarotoxin), by alpha7 nAChR short interfering RNA, and by inhibitors of phosphatidylinositol 3-kinase (PI3K; wortmannin and LY294002) and mammalian target of rapamycin (mTOR; rapamycin). In contrast, this effect was enhanced by PUN282987, an alpha7 nAChR agonist. Silencing of PPARbeta/delta attenuated the stimulatory effect of nicotine on cell growth, which was overcome by transfection of an exogenous PPARbeta/delta expression vector. Of note, nicotine induced complex formation between alpha7 nAChR and PPARbeta/delta protein and increased PPARbeta/delta gene promoter activity through inhibition of AP-2alpha as shown by reduced AP-2alpha binding using electrophoretic gel mobility shift and chromatin immunoprecipitation assays. In addition, silencing of Sp1 attenuated the effect of nicotine on PPARbeta/delta. Collectively, our results show that nicotine increases PPARbeta/delta gene expression through alpha7 nAChR-mediated activation of PI3K/mTOR signals that inhibit AP-2alpha protein expression and DNA binding activity to the PPARbeta/delta gene promoter. Sp1 seems to modulate this process. This study unveils a novel mechanism by which nicotine promotes human lung carcinoma cell growth.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bungarotoxins / pharmacology
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Non-Small-Cell Lung / metabolism*
  • Cell Proliferation / drug effects
  • Cholinergic Agonists / pharmacology
  • Enzyme Activation / drug effects
  • Enzyme Activation / physiology
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism*
  • Models, Biological
  • Nicotine / pharmacology*
  • PPAR delta / genetics
  • PPAR delta / metabolism*
  • PPAR-beta / genetics
  • PPAR-beta / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphatidylinositol 3-Kinases / physiology
  • Promoter Regions, Genetic / drug effects
  • Protein Kinases / metabolism*
  • Protein Kinases / physiology
  • Receptors, Nicotinic / physiology
  • TOR Serine-Threonine Kinases
  • Transcription Factor AP-2 / antagonists & inhibitors*
  • Transcription Factor AP-2 / metabolism
  • Tumor Cells, Cultured
  • Up-Regulation / drug effects
  • alpha7 Nicotinic Acetylcholine Receptor

Substances

  • Bungarotoxins
  • Cholinergic Agonists
  • Chrna7 protein, human
  • PPAR delta
  • PPAR-beta
  • Receptors, Nicotinic
  • Transcription Factor AP-2
  • alpha7 Nicotinic Acetylcholine Receptor
  • Nicotine
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases